

# Johann Sebastian de Bono

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3369798/johann-sebastian-de-bono-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

692 papers	59,643 citations	110 h-index	235 g-index
843 ext. papers	71,962 ext. citations	8.4 avg, IF	7.4 L-index

#	Paper	IF	Citations
692	Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.. <i>Lancet</i>	21.7	2
691	BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotypePhase 2a interim results.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 125-126	2.2	0
690	TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)Exploration of germline DDR alteration landscape and potential associations with antitumor activity.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 157-157	2.2	0
689	A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.. <i>Molecular Cancer</i> , <b>2022</b> , 21, 82	42.1	0
688	H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119, e2114324119	11.5	2
687	Neutropenia, neutrophilia, and neutrophil/lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 175883592211000	5.4	0
686	Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. <i>European Urology Focus</i> , <b>2021</b> , 7, 752-763	5.1	5
685	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.. <i>Lancet, The</i> , <b>2021</b> ,	40	18
684	HER3 is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> ,	10.1	2
683	Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. <i>Science</i> , <b>2021</b> , 374, 216-224	33.3	28
682	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating VβVβ T cell-mediated antitumor immune response. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabj0835	17.5	6
681	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. <i>International Journal of Cancer</i> , <b>2021</b> ,	7.5	4
680	Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility. <i>European Urology Focus</i> , <b>2021</b> , 7, 231-233	5.1	1
679	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 298-301	21.7	9
678	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. <i>Japanese Journal of Clinical Oncology</i> , <b>2021</b> , 51, 1287-1297	2.8	1
677	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 454-467	19.4	4
676	Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3602-3609	12.9	7

675	RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2334-2353	24.4	9
674	An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , <b>2021</b> , 6, 100089	6	1
673	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2812-2827	24.4	15
672	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. <i>Oncologist</i> , <b>2021</b> , 26, e1179-e1188	5.7	1
671	Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5013-5013	2.2	4
670	A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS3153-TPS3153	2.2	1
669	Phase 1 trial of the adenosine A2A receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2562-2562	2.2	4
668	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5047-5047	2.2	0
667	Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
666	Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS5088-TPS5088	2.2	5
665	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	3
664	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2021</b> , 41, e190-e202	7.1	3
663	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , <b>2021</b> , 79, 736-746	10.2	0
662	HER3 expression and MEK activation in non-small-cell lung carcinoma. <i>Lung Cancer Management</i> , <b>2021</b> , 10, LMT48	2.6	1
661	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre international retreat. <i>Canadian Urological Association Journal</i> , <b>2021</b> , 15, E623-E629	1.2	0
660	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 398, 131-142	4 <sup>0</sup>	27
659	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , <b>2021</b> , 79, 200-211	10.2	24
658	Characterizing CDK12-Mutated Prostate Cancers. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 566-574	12.9	17

657	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , <b>2021</b> , 11, 80-91	24.4	45
656	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 391-398	8.7	2
655	Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 438-446	12.9	6
654	AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 28, 100218	2	0
653	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1118-1137	24.4	41
652	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 27, 100309	2	2
651	CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 161-161	2.2	0
650	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , <b>2021</b> , 81, 1087-1100	10.1	5
649	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 13-13	2.2	7
648	SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer (mCRPC) A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 107-107	2.2	
647	Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 155-155	2.2	
646	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2340-2351	12.9	4
645	Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 27-27	2.2	7
644	Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2021.03.024">https://doi.org/10.1016/j.eururo.2021.03.024</a>	10.2	
643	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3K Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	4
642	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , <b>2021</b> , 80, 243-253	10.2	3
641	A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2021</b> ,	17.9	3
640	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 1250-1264	21.7	24

639	Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Targeted Oncology</i> , <b>2021</b> , 16, 613-623	5	2
638	Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1091-1103	59.2	202
637	Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT). <i>BMJ Open</i> , <b>2021</b> , 11, e049217	3	0
636	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , <b>2021</b> , 80, 497-506	10.2	3
635	Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD Study. <i>ESMO Open</i> , <b>2021</b> , 6, 100241	6	2
634	LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , <b>2020</b> , 31, S1153-S1154	10.3	18
633	621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. <i>Annals of Oncology</i> , <b>2020</b> , 31, S513-S514	10.3	4
632	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkaa003	4.6	1
631	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non--Mutant Cancers. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1528-1543	24.4	37
630	Prostate carcinogenesis: inflammatory storms. <i>Nature Reviews Cancer</i> , <b>2020</b> , 20, 455-469	31.3	38
629	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3195-3204	2.2	63
628	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1324-1332	8.7	11
627	Elucidating Durable Responses to Immune Checkpoint Inhibition. <i>European Urology</i> , <b>2020</b> , 78, 639-641	10.2	1
626	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , <b>2020</b> , 31, 619-625	10.3	29
625	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , <b>2020</b> , 72, 100837	16.7	4
624	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 801-811	8.7	30
623	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , <b>2020</b> , 77, 508-547	10.2	155
622	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 2091-2102	59.2	550

621	Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab <b>2020</b> , 8,		5
620	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4805-4813	12.9	5
619	Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation. <i>Metabolomics</i> , <b>2020</b> , 16, 50	4.7	0
618	389 Combining transcriptomic- and tissue-based immune biomarkers to evaluate GB1275, a CD11b modulator, as a single agent or with pembrolizumab in patients with advanced solid tumors <b>2020</b> , 8, A414-A414		
617	316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A <b>2020</b> , 8, A342-A342		2
616	388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors <b>2020</b> , 8, A413-A413		1
615	CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 2435-2450	15.9	6
614	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 1743-1751	15.9	85
613	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5875-5892	15.9	21
612	The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3987-4005	15.9	14
611	BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 3618-3618	2.2	4
610	Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS): Analyses from a randomized phase II trial in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5508-5508	2.2	3
609	Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5526-5526	2.2	5
608	Impact of olaparib vs physician's choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5538-5538	2.2	1
607	Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5539-5539	2.2	4
606	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5543-5543	2.2	7
605	Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5544-5544	2.2	3
604	First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5552-5552	2.2	10



603	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5559-5559	2.2	1
602	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRM) and metastatic castration-resistant prostate cancer (mCRPC) [Updated interim analysis (IA)].. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5566-5566	2.2	8
601	KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 100-100	2.2	21
600	KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 102-102	2.2	7
599	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 103-103	2.2	6
598	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 134-134	2.2	4
597	Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 15-15	2.2	12
596	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 182-182	2.2	6
595	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5569-5569	2.2	0
594	Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5558-5558	2.2	
593	Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5550-5550	2.2	2
592	Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5545-5545	2.2	3
591	Genetic Analysis of Circulating Tumour Cells. <i>Recent Results in Cancer Research</i> , <b>2020</b> , 215, 57-76	1.5	6
590	First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1730-1736	8.7	26
589	Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1117-1128	4.3	3
588	Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1096-1107	4.3	3
587	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. <i>JNCI Cancer Spectrum</i> , <b>2020</b> , 4, pkz093	4.6	62
586	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2020</b> , 6, 217-225	13.4	10

585	Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1220-1228	12.9	36
584	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 395-405	2.2	216
583	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 162-174	21.7	244
582	Prostate Cancer 2020: "The Times They Are a'Changing". <i>Cancer Cell</i> , <b>2020</b> , 38, 25-27	24.3	8
581	610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , <b>2020</b> , 31, S508	10.3	4
580	Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1478-1488	21.7	18
579	Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	7
578	625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. <i>Annals of Oncology</i> , <b>2020</b> , 31, S516-S517	10.3	2
577	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2345-2357	59.2	143
576	A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 889-891	21.7	2
575	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1513-1525	21.7	13
574	Targeting defective DNA repair in prostate cancer. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 503-509	4.2	3
573	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. <i>European Urology Oncology</i> , <b>2020</b> , 3, 540-543	6.7	6
572	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , <b>2020</b> , 3, 176-182	6.7	10
571	Diverse Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1965-1976	12.9	28
570	Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 719-728	10.2	75
569	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2506-2518	59.2	219
568	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4624-4633	12.9	10



567	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1437-1447	14.3	218
566	Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. <i>Oncogene</i> , <b>2019</b> , 38, 5700-5724	9.2	34
565	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 676-685	10.2	41
564	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 2580-2592	10.1	42
563	Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 383-393	21.7	64
562	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 928-936	12.9	161
561	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 75, 285-293	10.2	83
560	Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer. <i>Cell Reports</i> , <b>2019</b> , 28, 2156-2168.e5	10.6	59
559	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 469-478	10.2	114
558	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in -Mutant Cancers. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1396-1404	6.1	8
557	Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2182-2184	2.2	9
556	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , <b>2019</b> , 292, 273-286	20.5	24
555	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , <b>2019</b> , 30, v881-v882	10.3	45
554	Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2019</b> , 76, 843-851	10.2	21
553	First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3007-3007	2.2	21
552	PIPA: A phase Ib study of selective Isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor tasisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancersSafety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3087-3087	2.2	2
551	PSMA heterogeneity and DNA repair defects in prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5002-5002	2.2	1
550	TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5005-5005	2.2	28

549	Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5010-5010	2.2	3
548	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5027-5027	2.2	5
547	Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5070-5070	2.2	2
546	A phase Ib/II study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (NCT03431350).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS5087-TPS5087	2.2	2
545	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 145-145	2.2	38
544	Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 171-171	2.2	12
543	Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 216-216	2.2	8
542	Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 151-151	2.2	
541	Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18175-e18175	2.2	
540	Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3088-3088	2.2	
539	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , <b>2019</b> , 30, ix188-ix189	10.3	7
538	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. <i>European Urology</i> , <b>2019</b> , 76, 306-312	10.2	19
537	Immunotherapy for lethal prostate cancer. <i>Nature Reviews Urology</i> , <b>2019</b> , 16, 69-70	5.5	12
536	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , <b>2019</b> , 75, 184-192	10.2	49
535	Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. <i>European Urology</i> , <b>2019</b> , 75, 929-937	10.2	26
534	RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 687-697	12.9	26
533	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , <b>2019</b> , 75, 88-99	10.2	216
532	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 192-208	15.9	157

531	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , <b>2018</b> , 359, 920-926	33.3	712
530	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 694-701	13.4	32
529	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>European Urology</i> , <b>2018</b> , 74, 283-291	10.2	54
528	Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience. <i>Journal of Neuro-Oncology</i> , <b>2018</b> , 139, 107-116	4.8	3
527	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , <b>2018</b> , 50, 682-692	36.3	112
526	Second-generation antiandrogens in nonmetastatic CRPC. <i>Nature Reviews Urology</i> , <b>2018</b> , 15, 342-344	5.5	3
525	BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. <i>Cell Reports</i> , <b>2018</b> , 22, 796-808	10.6	57
524	Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. <i>European Urology</i> , <b>2018</b> , 73, 687-693	10.2	70
523	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 645-657	59.2	224
522	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , <b>2018</b> , 73, 715-723	10.2	71
521	Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 219-228	36.3	71
520	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1653-1654	59.2	37
519	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 645-651	36.3	380
518	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3149-3162	12.9	77
517	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , <b>2018</b> , 4, 235-244	5.1	12
516	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , <b>2018</b> , 73, 178-211	10.2	313
515	Reply to Finn E. von Eyben, Irene Virgolini and Giandomenico Roviello's Letter to the Editor re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>Eur Urol</i> <b>2018</b> ; 73: 178-211. <i>European Urology</i> , <b>2018</b> , 73, e32-e33	10.2	3
514	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for 24 weeks in Europe. <i>European Urology</i> , <b>2018</b> , 74, 37-45	10.2	59

513	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features. <i>Investigative Radiology</i> , <b>2018</b> , 53, 96-102	10.1	24
512	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 572-580	2.2	123
511	Health economic impact of liquid biopsies in cancer management. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2018</b> , 18, 593-599	2.2	18
510	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5585-5593	12.9	74
509	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2584-2591	7.5	46
508	Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. <i>European Journal of Cancer</i> , <b>2018</b> , 101, 55-61	7.5	5
507	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1554-1560	10.3	42
506	Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , <b>2018</b> , 12, 339-343	2.6	5
505	A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 757-766	3.5	2
504	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5635-5644	12.9	59
503	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 663-675	19.4	87
502	Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIDESTANA and PROCELLICA). <i>European Urology</i> , <b>2018</b> , 74, 100-101	10.2	
501	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , <b>2018</b> , 173, 1770-1782.e14	56.2	256
500	A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products. <i>PLoS ONE</i> , <b>2018</b> , 13, e0193689	3.7	10
499	Hypoxia and Noncoding RNAs in Taxane Resistance. <i>Trends in Pharmacological Sciences</i> , <b>2018</b> , 39, 695-709	13.2	16
498	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , <b>2018</b> , 1, 151-159	6.7	23
497	Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers. <i>European Urology Oncology</i> , <b>2018</b> , 1, 71-77	6.7	14
496	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 341-358	15.9	58

495	KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5007-5007	2.2	64
494	Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5013-5013	2.2	4
493	Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5064-5064	2.2	2
492	Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5070-5070	2.2	3
491	A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS391-TPS391	2.2	4
490	is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition. <i>Oncotarget</i> , <b>2018</b> , 9, 7604-7615	3.3	21
489	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , <b>2018</b> , 9, 19283-19293	3.3	37
488	Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against. <i>European Oncology and Haematology</i> , <b>2018</b> , 14, 14	0.1	
487	Consensus statement on circulating biomarkers for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 299-299	2.2	1
486	Clinical outcome of patients with germline DNA repair mutations: Results from a retrospective international study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 218-218	2.2	
485	Clinical and economic burden of serious adverse events (SAEs) in an early phase trials unit.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e18890-e18890	2.2	
484	A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 6586-6586	2.2	
483	The prognostic and predictive value of AR-V7 quantification in mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 12026-12026	2.2	
482	Early changes in PSA and association with outcomes in mCRPC patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5063-5063	2.2	
481	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. <i>Blood</i> , <b>2018</b> , 132, 3237-3237	2.2	
480	Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2018</b> , 73, 727-735	10.2	40
479	Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2018</b> , 8,	5.4	69
478	Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit. <i>Clinical Oncology</i> , <b>2018</b> , 30, 185-191	2.8	2



477	Reply to M. Horiguchi et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 826-827	2.2	1
476	Reply to C. Ren et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2354-2356	2.2	
475	EpCAM and EpCAM circulating tumor cells in metastatic prostate and breast cancer patients. <i>Oncotarget</i> , <b>2018</b> , 9, 35705-35716	3.3	48
474	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 4441-4453	15.9	84
473	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e696-e708	21.7	59
472	Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 922-927	8.7	2
471	Can Early Clinical Trials Help Deliver More Precise Cancer Care? <b>2018</b> , 115-128		
470	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1425-1433	8.7	35
469	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 280-284	3.8	22
468	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. <i>Nature</i> , <b>2018</b> , 559, 363-369	50.4	163
467	Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1187-1188	13.4	11
466	CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. <i>Nature</i> , <b>2018</b> , 559, 285-289	50.4	178
465	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , <b>2017</b> , 71, 81-92	10.2	150
464	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , <b>2017</b> , 71, 656-664	10.2	44
463	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2017</b> , 20, 221-227	6.2	34
462	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 473-485	21.7	58
461	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , <b>2017</b> , 7, 620-629	24.4	232
460	Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. <i>Cancer</i> , <b>2017</b> , 123, 2303-2311	6.4	23

459	CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1495-1507	10.3	64
458	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1006-1017	24.4	232
457	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e801-e807	3.3	15
456	Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 678-684.e1	3.3	12
455	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2315-2323	6.1	8
454	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K $\beta$ Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5015-5023	12.9	51
453	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 338-351	59.2	898
452	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2017</b> , 76, 36-44	7.5	48
451	Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , <b>2017</b> , 72, 10-13	10.2	19
450	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. <i>Radiology</i> , <b>2017</b> , 284, 88-99	20.5	33
449	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3101-3112	10.1	43
448	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 610-617.e3	3.3	18
447	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. <i>PLoS ONE</i> , <b>2017</b> , 12, e0186106	3.7	12
446	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m) and the Currently Approved Dose (25 mg/m) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3198-3206	2.2	147
445	Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. <i>ESMO Open</i> , <b>2017</b> , 2, e000101	6	6
444	RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 954-964	8.7	9
443	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , <b>2017</b> , 20, 1411-1419	3.3	5
442	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6070-6077	12.9	22

441	Application of Liquid Biopsies in Cancer Targeted Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 745-747	6.1	15
440	Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation. <i>Cancer Research</i> , <b>2017</b> , 77, 4745-4754	10.1	35
439	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5981-5992	12.9	73
438	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , <b>2017</b> , 241, 173-182	9.4	33
437	Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2016.06.033">http://dx.doi.org/10.1016/j.eururo.2016.06.033</a>	10.2	1
436	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , <b>2017</b> , 28, 90-95	10.3	19
435	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2017</b> , 120, E30-E44	5.6	47
434	DNA Repair in Prostate Cancer: Biology and Clinical Implications. <i>European Urology</i> , <b>2017</b> , 71, 417-425	10.2	132
433	Rationale for Modernising Imaging in Advanced Prostate Cancer. <i>European Urology Focus</i> , <b>2017</b> , 3, 223-239	3.9	46
432	Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2016.06.033">http://dx.doi.org/10.1016/j.eururo.2016.06.033</a>	10.2	
431	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1967-1973	12.9	36
430	A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 17-27	3.5	6
429	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , <b>2017</b> , 283, 168-177	20.5	57
428	Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. <i>Cancer</i> , <b>2017</b> , 123, 253-262	6.4	26
427	Heterogeneity of advanced prostate cancer: clinical implications of genomics. <i>Trends in Urology &amp; Men's Health</i> , <b>2017</b> , 8, 24-27	0.3	
426	Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). <i>Annals of Oncology</i> , <b>2017</b> , 28, v620	10.3	3
425	Abstract 4679: Mismatch repair defects in lethal prostate cancer <b>2017</b> ,		3
424	Abstract 993: Diagnostic leukapheresis (DLA): Molecular characterisation and organoid culture of circulating tumor cells (CTC) from metastatic castration resistant prostate cancer (mCRPC) <b>2017</b> ,		3

423	Clinical outcomes of adolescents and young adults (AYA) with advanced solid tumors participating in phase I trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 10536-10536	2.2	1
422	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2503-2503	2.2	8
421	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2506-2506	2.2	18
420	A first in human phase I study of AZD8186, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2570-2570	2.2	7
419	Clinical factors associated with AR-V7 detection in ARMOR3-SV, a randomized trial of galeterone (Gal) vs enzalutamide (Enz) in men with AR-V7+ metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5005-5005	2.2	20
418	Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5007-5007	2.2	3
417	Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5015-5015	2.2	2
416	Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 8556-8556	2.2	7
415	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, LBA5003-LBA5003	2.2	2
414	PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5091-TPS5091	2.2	8
413	Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, LBA5003-LBA5003	2.2	4
412	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 135-135	2.2	3
411	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 141-141	2.2	2
410	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 104430-104443	3.3	3
409	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , <b>2017</b> , 6,	8.9	23
408	A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2573-2573	2.2	1
407	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2571-2571	2.2	
406	A phase 1/1b multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in patients with metastatic, castration-resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS5088-TPS5088	2.2	

405	Adherence to novel oral anticancer therapies in the phase I setting: The Royal Marsden experience.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2542-2542	2.2	
404	Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5014-5014	2.2	
403	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5071-5071	2.2	
402	Prostate cancer. <i>Lancet, The</i> , <b>2016</b> , 387, 70-82	40	645
401	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , <b>2016</b> , 15, 699-718	64.1	77
400	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3005-13	2.2	163
399	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 362ps17	17.5	343
398	Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 4280-2	12.9	15
397	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 985-992	10.2	92
396	Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. <i>JAMA Oncology</i> , <b>2016</b> , 2, 471-80	13.4	38
395	Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2874-84	12.9	75
394	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 438-44	10.2	25
393	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 675-683	10.2	57
392	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. <i>Drugs</i> , <b>2016</b> , 76, 421-30	12.1	3
391	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. <i>European Journal of Cancer</i> , <b>2016</b> , 56, 93-100	7.5	50
390	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1402-18	2.2	666
389	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1652-9	2.2	217
388	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 724-731	10.2	47



387	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1163-77	40	1115
386	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 348-57	13.4	108
385	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , <b>2016</b> , 69, 924-32	10.2	20
384	Abstract 2243: Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts) <b>2016</b> ,		2
383	Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations <b>2016</b> ,		10
382	Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2043-2043	2.2	1
381	Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2504-2504	2.2	21
380	Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2582-2582	2.2	4
379	Phase III non-inferiority study of cabazitaxel (C) 20 mg/m <sup>2</sup> (C20) versus 25 mg/m <sup>2</sup> (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5008-5008	2.2	25
378	Inherited mutations in DNA repair genes in men with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5009-5009	2.2	1
377	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5014-5014	2.2	3
376	Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5017-5017	2.2	9
375	Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5028-5028	2.2	1
374	High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5076-5076	2.2	3
373	Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant (ARMOR3-SV).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS5085-TPS5085	2.2	1
372	Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 182-182	2.2	1
371	Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 273-273	2.2	
370	PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 278-278	2.2	

- 369 Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.. *Journal of Clinical Oncology*, **2016**, 34, 213-213 2.2
- 368 Interrogating metastatic prostate cancer treatment switch decisions.. *Journal of Clinical Oncology*, **2016**, 34, 296-296 2.2
- 367 Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis.. *Journal of Clinical Oncology*, **2016**, 34, 280-280 2.2
- 366 Cabazitaxel for the Treatment of Prostate Cancer **2016**, 187-214
- 365 Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.. *Journal of Clinical Oncology*, **2016**, 34, 168-168 2.2
- 364 Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. *Journal of Clinical Oncology*, **2016**, 34, 266-266 2.2
- 363 Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases.. *Journal of Clinical Oncology*, **2016**, 34, 2568-2568 2.2
- 362 Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH).. *Journal of Clinical Oncology*, **2016**, 34, e14048-e14048 2.2
- 361 Quantifying patients' motivations for phase I oncology trials and how expectations change at the first clinical consultation.. *Journal of Clinical Oncology*, **2016**, 34, 10061-10061 2.2
- 360 Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases.. *Journal of Clinical Oncology*, **2016**, 34, 11579-11579 2.2
- 359 Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. *Journal of Clinical Oncology*, **2016**, 34, 5062-5062 2.2
- 358 A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.. *Journal of Clinical Oncology*, **2016**, 34, 2571-2571 2.2
- 357 Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU).. *Journal of Clinical Oncology*, **2016**, 34, 11508-11508 2.2
- 356 Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts.. *Journal of Clinical Oncology*, **2016**, 34, 5042-5042 2.2
- 355 Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. *Journal of Clinical Oncology*, **2016**, 34, 5043-5043 2.2
- 354 Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. *Archivio Italiano Di Urologia Andrologia*, **2016**, 88, 72-3 1.6
- 353 Interrogating the Cancer Genome to Deliver More Precise Cancer Care. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, e577-83 7.1 1
- 352 Abiraterone for the Treatment of mCRPC **2016**, 125-155

351	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 443-53	59.2	791
350	Reply to A. Addeo and A. Bahl. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 387-8	2.2	
349	The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality. <i>Trends in Cancer</i> , <b>2016</b> , 2, 646-656	12.5	14
348	Targeted $\beta$ -Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1838-1839	8.9	6
347	Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2016</b> , 22, 353-356	2.2	19
346	Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging. <i>Journal of Algorithms and Computational Technology</i> , <b>2016</b> , 10, 290-301	0.7	7
345	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , <b>2016</b> , 2, 488-498	5.1	29
344	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , <b>2016</b> , 280, 151-60	20.5	36
343	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 485-493	3.3	21
342	Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Eur Urol</i> 2016;70:724-31. <i>European Urology</i> , <b>2016</b> , 70, e170-e171	10.2	
341	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , <b>2016</b> , 76, 2731-42	10.1	64
340	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1412-24	6.1	14
339	Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 599-608	10.2	90
338	Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2431-2	2.2	6
337	A study of motivations and expectations of patients seen in phase 1 oncology clinics. <i>Cancer</i> , <b>2016</b> , 122, 3501-3508	6.4	23
336	Is there an antiandrogen withdrawal syndrome with enzalutamide?. <i>BJU International</i> , <b>2015</b> , 115, 373-80	5.6	26
335	Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e205-e208	3.3	23
334	Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1356-63	2.2	92

333	Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. <i>European Urology</i> , <b>2015</b> , 67, 866-73	10.2	35
332	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , <b>2015</b> , 67, 1028-1038	10.2	255
331	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4586-96	12.9	154
330	Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function. <i>Molecular Cell</i> , <b>2015</b> , 58, 925-34.6	14.6	102
329	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 509-21	21.7	138
328	Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1869-76	12.9	28
327	Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1348-55	2.2	295
326	Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1305-12	12.9	32
325	Targeting extra-gonadal androgens in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2015</b> , 145, 157-63	5.1	11
324	The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2297-2304	12.9	53
323	First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3412-9	12.9	92
322	Cabozantinib-Getting Under the Skin of Cutaneous Toxicity. <i>JAMA Oncology</i> , <b>2015</b> , 1, 535-6	13.4	4
321	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1697-708	59.2	1345
320	Plasma AR and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 312re10	17.5	301
319	Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin. <i>Histopathology</i> , <b>2015</b> , 66, 898-901	7.3	19
318	A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. <i>BMC Medicine</i> , <b>2015</b> , 13, 201	11.4	12
317	A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2015</b> , 4, 277-85	4.5	20
316	A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2275-84	7.5	19

315	Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors. <i>Oncologist</i> , <b>2015</b> , 20, 368-9	5.7	5
314	CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4992-5	12.9	11
313	Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. <i>European Urology</i> , <b>2015</b> , 67, 310-8	10.2	32
312	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , <b>2015</b> , 68, 317-24	10.2	78
311	Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. <i>European Urology</i> , <b>2015</b> , 67, 223-30	10.2	25
310	343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). <i>European Journal of Cancer</i> , <b>2015</b> , 51, S68	7.5	2
309	Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). <i>BJU International</i> , <b>2015</b> , 116, 880-7	5.6	30
308	MP87-18 ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS). <i>Journal of Urology</i> , <b>2015</b> , 193, 1033	2.5	2
307	What have we learned from exceptional tumour responses?: Review and perspectives. <i>Current Opinion in Oncology</i> , <b>2015</b> , 27, 267-75	4.2	7
306	SPOP mutation leads to genomic instability in prostate cancer. <i>ELife</i> , <b>2015</b> , 4,	8.9	110
305	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
304	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , <b>2015</b> , 68, 570-7	10.2	41
303	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 679-90	4.3	38
302	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology</i> , <b>2015</b> , 16, e279-92	21.7	123
301	PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1225-33	8.7	72
300	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , <b>2015</b> , 12, 37-47	5.5	49
299	First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 77-86	12.9	217
298	PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. <i>European Urology</i> , <b>2015</b> , 67, 795-802	10.2	143



297	Enzalutamide in European and North American men participating in the AFFIRM trial. <i>BJU International</i> , <b>2015</b> , 115, 41-9	5.6	11
296	A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 673-9	10.2	59
295	Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1621-7	12.9	46
294	Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5009-5009	2.2	100
293	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , <b>2015</b> , 16, 152-60	21.7	856
292	Antitumor activity in RAS-driven tumors by blocking AKT and MEK. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 739-48	12.9	104
291	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients <b>2015</b> ,		10
290	Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors <b>2015</b> ,		2
289	A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2566-2566	2.2	5
288	A phase I, first-in-human study to evaluate the tolerability, pharmacokinetics and preliminary efficacy of HuMax-tissue factor-ADC (TF-ADC) in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2570-2570	2.2	3
287	The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5000-5000	2.2	19
286	Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5009-5009	2.2	11
285	Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5014-5014	2.2	5
284	Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5035-5035	2.2	13
283	Enzalutamide (ENZA) in men with chemotherapy-Naïve metastatic castration-resistant prostate cancer (mCRPC): Final analysis of the phase 3 PREVAIL study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5036-5036	2.2	5
282	Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV) Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC) expressing AR-V7 splice variant.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5036-5036	2.2	3
281	Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 139-139	2.2	21
280	Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 144-144	2.2	16

279	Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (Pts).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 169-169	2.2	0
278	Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 184-184	2.2	8
277	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 187-187	2.2	5
276	Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 215-215	2.2	3
275	Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 268-268	2.2	2
274	Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 142-142	2.2	
273	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5051-5051	2.2	
272	Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5596-5596	2.2	
271	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2014</b> , 39, 1049-78	5.6	79
270	Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, dju033	9.7	57
269	Circulating tumor cells: a multifunctional biomarker. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2553-68	12.9	151
268	Evolution of androgen receptor targeted therapy for advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 365-76	19.4	125
267	Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 170-7	14.4	34
266	The promise of circulating tumor cell analysis in cancer management. <i>Genome Biology</i> , <b>2014</b> , 15, 448	18.3	38
265	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 2248-53	8.7	45
264	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 1147-56	21.7	154
263	Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 555-66	9.6	38
262	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 995-1004	4.3	44

261	Enzalutamide in metastatic prostate cancer before chemotherapy. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 424-33	59.2	1892
260	Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. <i>European Urology</i> , <b>2014</b> , 66, 459-65	10.2	116
259	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , <b>2014</b> , 66, 815-25	10.2	186
258	New Therapies in Hormone Relapsed Disease <b>2014</b> , 265-286		
257	P623RGS-1 modulates leukocyte trafficking in atherosclerosis and aortic aneurysm formation through chemokine receptor desensitisation. <i>Cardiovascular Research</i> , <b>2014</b> , 103, S113.1-S113	9.9	
256	Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , e197-203	7.1	14
255	Response Rates and Outcomes with Enzalutamide for Patients with Metastatic Castration Resistant Prostate Cancer and Visceral Disease in the Prevail Trial. <i>Annals of Oncology</i> , <b>2014</b> , 25, iv262	10.3	2
254	A Phase 1/2 Study of At13387, a Heat Shock Protein 90 (Hsp90) Inhibitor in Combination with Abiraterone Acetate (Aa) and Prednisone (P) in Patients (Pts) with Castration-Resistant Prostate Cancer (Mcrpc) No Longer Responding to Aa. <i>Annals of Oncology</i> , <b>2014</b> , 25, iv267	10.3	2
253	Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3391-9	2.2	101
252	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , <b>2014</b> , 120, 3346-52	6.4	98
251	Safety and efficacy of multipolar pulmonary vein ablation catheter vs. irrigated radiofrequency ablation for paroxysmal atrial fibrillation: a randomized multicentre trial. <i>Europace</i> , <b>2014</b> , 16, 1145-53	3.9	39
250	Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5672-85	12.9	61
249	Molecular pathology and prostate cancer therapeutics: from biology to bedside. <i>Journal of Pathology</i> , <b>2014</b> , 232, 178-84	9.4	26
248	A Randomized Phase 3 Study Comparing First-Line Docetaxel/Prednisone (Dp) to Dp Plus Custirsen in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc). <i>Annals of Oncology</i> , <b>2014</b> , 25, iv256	10.3	5
247	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 254ra125	17.5	256
246	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 219-31	3.6	24
245	Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1925-34	12.9	29
244	Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1042-3	7.5	

243	External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. <i>European Urology</i> , <b>2014</b> , 66, 8-11	10.2	19
242	Visceral disease in castration-resistant prostate cancer. <i>European Urology</i> , <b>2014</b> , 65, 270-273	10.2	126
241	PI-05 LATE-BREAKING ABSTRACT: THE PREVAIL STUDY: PRIMARY AND NON-VISCERAL / VISCERAL DISEASE SUBGROUP RESULTS FOR ENZALUTAMIDE-TREATED MEN WITH METASTATIC PROSTATE CANCER (MPC) THAT HAD PROGRESSED ON ADT. <i>Journal of Urology</i> , <b>2014</b> , 191,	2.5	1
240	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. <i>Gastric Cancer</i> , <b>2014</b> , 17, 621-629	7.6	6
239	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , <b>2014</b> , 7, 1	22.4	104
238	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , <b>2014</b> , 33, 567-79	9.6	24
237	A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2514-2514	2.2	17
236	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2607-2607	2.2	2
235	Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2622-2622	2.2	4
234	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5007-5007	2.2	2
233	Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5042-5042	2.2	2
232	Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5054-5054	2.2	1
231	Characterization of ovarian cancer long-term responders on olaparib.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5534-5534	2.2	1
230	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7522-7522	2.2	20
229	Dual targeting of RAF-MEK-ERK and PI3K-AKT-mTOR pathways in RAS-mutant cancers: Preclinical insights and institutional experience from a clinical trial of binimetinib (MEK162) plus BYL719.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e13559-e13559	2.2	3
228	Effect of concomitant medication use on outcomes of treatment and placebo arms of the COU-AA-301 and COU-AA-302 studies of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e16045-e16045	2.2	3
227	A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS5097-TPS5097	2.2	3
226	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 14-14	2.2	4

225	Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 20-20	2.2	3
224	Is there an anti-androgen withdrawal effect with enzalutamide?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 200-200	2.2	1
223	CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 209-209	2.2	3
222	Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 21-21	2.2	2
221	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7-7	2.2	13
220	A prognostic score for patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 70-70	2.2	3
219	Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 78-78	2.2	3
218	Enzalutamide in men with chemotherapy-naïve metastatic prostate cancer (mCRPC): Results of phase III PREVAIL study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, LBA1-LBA1	2.2	29
217	Reappraisal of glucocorticoids in castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 666	2.8	5
216	Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2024-2024	2.2	
215	What factors influence advanced ovarian cancer patient (AOC pt) outcomes to phase I trial treatments?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5560-5560	2.2	
214	Complications of hyperglycemia in phase 1 trials targeting the PI3K-akt-mTOR (PAM) pathway.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2612-2612	2.2	
213	Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in pts (pts) referred for phase I trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 11051-11051	2.2	
212	Prognostic significance of the neutrophil-lymphocyte ratio (NLR) in phase 1 clinical trial patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3037-3037	2.2	
211	Predictive factors of survival for patients with bladder cancer (BC) in phase I clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15525-e15525	2.2	
210	A study of risk of infection with drugs targeting the PI3 kinase (PI3K), AKT, and mTOR pathway.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2608-2608	2.2	
209	Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5013-5013	2.2	
208	Predicting response to abiraterone acetate (AA): mRNA biomarker analysis of study COU-AA-302.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 5058-5058	2.2	1



207 Phase III Targeted Treatments. *Current Clinical Urology*, **2014**, 177-186

206 PARP Inhibitors. *Current Clinical Urology*, **2014**, 253-264

205 Predicting positive bone marrow biopsies (BMBs) in patients (PTS) with advanced prostate cancer (APC).. *Journal of Clinical Oncology*, **2014**, 32, 180-180 2.2

204 Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development.. *Journal of Clinical Oncology*, **2014**, 32, 222-222 2.2

203 The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. *Lancet Oncology, The*, **2013**, 14, 882-92 21.7 410

202 New treatment developments applied to elderly patients with advanced prostate cancer. *Cancer Treatment Reviews*, **2013**, 39, 578-83 14.4 18

201 A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. *Cancer Chemotherapy and Pharmacology*, **2013**, 71, 1041-50 3.5 175

200 785 EFFICACY OUTCOMES BY BASELINE PROSTATE-SPECIFIC ANTIGEN (PSA): RESULTS FROM THE PHASE 3 AFFIRM TRIAL. *Journal of Urology*, **2013**, 189, 2.5 1

199 Appraising iniparib, the PARP inhibitor that never was--what must we learn?. *Nature Reviews Clinical Oncology*, **2013**, 10, 688-96 19.4 66

198 Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. *Clinical Cancer Research*, **2013**, 19, 5485-93 12.9 103

197 Development of therapeutic combinations targeting major cancer signaling pathways. *Journal of Clinical Oncology*, **2013**, 31, 1592-605 2.2 194

196 Management of patients with castration-resistant disease. *Hematology/Oncology Clinics of North America*, **2013**, 27, 1243-60, ix 3.1 2

195 Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors. *Cancer Chemotherapy and Pharmacology*, **2013**, 72, 1213-22 3.5 14

194 Abiraterone in metastatic prostate cancer without previous chemotherapy. *New England Journal of Medicine*, **2013**, 368, 138-48 59.2 1940

193 Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. *Journal of Pathology*, **2013**, 229, 422-9 9.4 235

192 Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. *Lancet Oncology, The*, **2013**, 14, 1307-16 21.7 169

191 713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL. *Journal of Urology*, **2013**, 189, 2.5 1

190 Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. *European Urology*, **2013**, 64, 300-6 10.2 70

189	715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279). <i>Journal of Urology</i> , <b>2013</b> , 189,	2.5	1
188	Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 75-84	5.5	10
187	Drugs for Cancer <b>2013</b> , 270-285		
186	Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. <i>Annual Review of Medicine</i> , <b>2013</b> , 64, 1-13	17.4	35
185	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3648-57	7.5	68
184	Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 909-16	3.5	16
183	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 760-8	4.3	220
182	First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5494-504	12.9	38
181	Agents that target androgen synthesis in castration-resistant prostate cancer. <i>Cancer Journal (Sudbury, Mass.)</i> , <b>2013</b> , 19, 34-42	2.2	16
180	Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1729-37	9.7	113
179	A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 900-8	12.9	85
178	Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3944-50	2.2	71
177	Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2791-8	2.2	90
176	A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4262-72	12.9	80
175	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1416-8	10.3	54
174	Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. <i>BJU International</i> , <b>2013</b> , 111, 697-9	5.6	26
173	Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. <i>Journal of Clinical Pharmacology</i> , <b>2013</b> , 53, 1020-7	2.9	28
172	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 2579-86	8.7	66

171	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e67148	3.7	68
170	Abstract C295: Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. <b>2013</b> ,		7
169	Abstract 2433: In vitro and in vivo antitumor activity of the next generation HSP90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models. <b>2013</b> ,		3
168	First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 2580-2580	2.2	39
167	A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4511-4511	2.2	7
166	First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5052-5052	2.2	2
165	A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 123-123	2.2	2
164	Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 14-14	2.2	2
163	Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 155-155	2.2	9
162	Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 16-16	2.2	7
161	Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 17-17	2.2	2
160	Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 20-20	2.2	2
159	Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 6-6	2.2	25
158	Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 62-62	2.2	1
157	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 91-91	2.2	1
156	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA8-LBA8	2.2	24
155	Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 22-22	2.2	
154	Outcome of patients (pts) with relapsed, advanced upper gastrointestinal (GI) carcinoma treated in a specialist oncology phase I unit.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 45-45	2.2	

153	A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 24-24	2.2	
152	Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. <i>Drug Discovery Today</i> , <b>2012</b> , 17, 221-6	8.8	31
151	Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 360, 68-75	4.4	24
150	Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. <i>BJU International</i> , <b>2012</b> , 110, 658-67	5.6	14
149	Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 316-26	4.3	8
148	Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1187-97	59.2	3075
147	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1114-24	21.7	97
146	Cabazitaxel in metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2012</b> , 12, 1129-36	3.5	20
145	Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. <i>Cancer Research</i> , <b>2012</b> , 72, 2176-82	10.1	205
144	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. <i>EPMA Journal</i> , <b>2012</b> , 3, 3	8.8	20
143	The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 1609-17	6.1	68
142	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , <b>2012</b> , 13, 168	2.8	94
141	Management of metastatic castration-resistant prostate cancer: recent advances. <i>Drugs</i> , <b>2012</b> , 72, 1011-28	28.1	28
140	PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. <i>Drugs</i> , <b>2012</b> , 72, 1579-90	12.1	25
139	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 983-92	21.7	965
138	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1210-7	21.7	225
137	Therapeutic options for advanced prostate cancer: 2011 update. <i>Current Urology Reports</i> , <b>2012</b> , 13, 170-8	8.9	12
136	FGF receptor inhibitors: role in cancer therapy. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 111-9	6.3	44

135	Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 507-16	5.6	199
134	Targeting the DNA damage response in oncology: past, present and future perspectives. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 316-24	4.2	42
133	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2943-2947	10.3	195
132	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. <i>Modern Pathology</i> , <b>2012</b> , 25, 902-10	9.8	44
131	MDV3100 for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 227-33	5.9	26
130	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2687-94	12.9	57
129	Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1241-1249	10.3	43
128	A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following	2.2	3
127	Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA4518-LBA4518	2.2	25
126	Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 17-17	2.2	7
125	Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 44-44	2.2	4
124	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA1-LBA1	2.2	44
123	Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. <i>PLoS ONE</i> , <b>2012</b> , 7, e47020	3.7	119
122	Prostate-specific antigen decline (PSA) as a surrogate for overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) who failed first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4515-4515	2.2	0
121	Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 6-6	2.2	
120	7105 POSTER DISCUSSION Belinostat in Combination With Carboplatin and Paclitaxel (BelCaP) for Treatment of Bladder Cancer [A Pharmacokinetic Study of Exposure to Belinostat and Its Metabolites. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S506	7.5	3
119	7015 POSTER DISCUSSION Fatigue Improvement/Reduction With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel [Results From the COU-AA-301 Phase 3 Study. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S488-S489	7.5	5
118	New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1649-57	12.9	130



117	Utilizing circulating tumor cells: challenges and pitfalls. <i>Current Opinion in Genetics and Development</i> , <b>2011</b> , 21, 50-8	4.9	87
116	Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , <b>2011</b> , 47 Suppl 3, S189-94	7.5	3
115	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S159	7.5	2
114	Cabazitaxel for castration-resistant prostate cancer [Authors' reply. <i>Lancet, The</i> , <b>2011</b> , 377, 122-123	4.0	10
113	First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers. <i>Gynecologic Oncology</i> , <b>2011</b> , 120, S5-S6	4.9	2
112	Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2011</b> , 61, 31-49	220.7	144
111	New therapies for castration-resistant prostate cancer: efficacy and safety. <i>European Urology</i> , <b>2011</b> , 60, 279-90	10.2	111
110	Beyond hormone therapy for prostate cancer with PARP inhibitors. <i>Cancer Cell</i> , <b>2011</b> , 19, 573-4	24.3	14
109	Clinical benefit of early phase clinical trial participation for advanced sarcoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 423-9	3.5	12
108	Flexible trial design in practice [Dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. <i>Trials</i> , <b>2011</b> , 12,	2.8	7
107	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , <b>2011</b> , 71, 1264-75	4.2	14
106	External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. <i>Cytometry Part B - Clinical Cytometry</i> , <b>2011</b> , 80, 112-8	3.4	87
105	Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1293-304	5.9	22
104	The changing therapeutic landscape of castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 8, 597-610	19.4	118
103	Abiraterone and increased survival in metastatic prostate cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1995-2005	59.2	3019
102	Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3420-30	12.9	114
101	Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5188-96	12.9	24
100	A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 581-8	12.9	88

99	Belinostat: clinical applications in solid tumors and lymphoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1723-32	5.9	25
98	Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress. <i>Cancer Discovery</i> , <b>2011</b> , 1, 207-12	24.4	17
97	Reporting the capture efficiency of a filter-based microdevice: a CTC is not a CTC unless it is CD45 negative--letter. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3048-9; author reply 3050	12.9	17
96	First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4688-95	2.2	444
95	Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3867-75	12.9	48
94	Prostate cancer: evolution or revolution?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3595-8	2.2	8
93	Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1728-35	2.2	98
92	Revisiting the role of antiandrogen strategies in ovarian cancer. <i>Oncologist</i> , <b>2011</b> , 16, 1413-21	5.7	18
91	Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. <i>Oncologist</i> , <b>2011</b> , 16, 1487-97	5.7	21
90	Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. <i>PLoS ONE</i> , <b>2011</b> , 6, e27419	3.7	36
89	Hormone treatment for prostate cancer <b>2011</b> , 46-52		
88	Translating cancer research into targeted therapeutics. <i>Nature</i> , <b>2010</b> , 467, 543-9	50.4	269
87	Envisioning the future of early anticancer drug development. <i>Nature Reviews Cancer</i> , <b>2010</b> , 10, 514-23	31.3	232
86	Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1489-95	2.2	331
85	Targeting insulin-like growth factor signaling: rational combination strategies. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2447-9	6.1	18
84	Abiraterone acetate is well tolerated without concomitant use of corticosteroids. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e560-1; author reply e562	2.2	30
83	Targeting the HGF/c-Met axis: state of play. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 1077-9	6.1	34
82	Reply to J. Veeck et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e565-e566	2.2	13

81	Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 6150-8	12.9	90
80	Early oncology clinical trial design in the era of molecular-targeted agents. <i>Future Oncology</i> , <b>2010</b> , 6, 1339-52	3.6	10
79	Poly(ADP-ribose) polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2512-9	2.2	737
78	Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 9-20	7.5	95
77	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1147-54	4.0	2311
76	Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 129-35	21.7	280
75	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3965-72	2.2	291
74	Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1496-501	2.2	345
73	Horizon scanning for novel therapeutics for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 1487-502	5.9	3
72	Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 765-73	3.5	153
71	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. <i>Drug Discovery Today</i> , <b>2010</b> , 15, 88-97	8.8	57
70	Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.. <i>Blood</i> , <b>2010</b> , 116, 1787-1787	2.2	
69	Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3177-83	12.9	92
68	Targeting the PI3K/AKT pathway for the treatment of prostate cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4799-805	12.9	272
67	Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. <i>Cancer Research</i> , <b>2009</b> , 69, 4937-40	10.1	134
66	Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3742-8	2.2	469
65	Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 6152-9	2.2	85
64	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic CastrationResistant Prostate Cancer: Missing Parts in a Superb Study: Table 1.. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1504.2-1505	12.9	5

63	Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2077-8	6.1	11
62	A first-in-man phase I and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4978-85	12.9	24
61	Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2692-6	2.2	139
60	Steroid hormone receptors in prostate cancer: a hard habit to break?. <i>Cancer Cell</i> , <b>2009</b> , 16, 458-62	24.3	173
59	A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 425-9	3.5	24
58	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 65, 167-75	3.5	2
57	A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. <i>Prostate</i> , <b>2009</b> , 69, 1507-20	4.2	6
56	From darkness to light with biomarkers in early clinical trials of cancer drugs. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 85, 131-3	6.1	28
55	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 123-34	59.2	2786
54	168 Circulating tumour cells as biomarkers in clinical trials. <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 42-43	1.6	
53	1204 A Phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 121	1.6	3
52	Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 2912-8	10.1	466
51	Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 233-9	21.7	476
50	Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2009</b> , 15, 406-20	2.2	133
49	A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3503-3503	2.2	27
48	Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3507-3507	2.2	5
47	Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e14519-e14519	2.2	2
46	Reovirus: Rationale and clinical trial update. <i>Current Opinion in Molecular Therapeutics</i> , <b>2009</b> , 11, 532-9		25

45	Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1365-1365	8.7	1
44	Targeting CYP17: established and novel approaches in prostate cancer. <i>Current Opinion in Pharmacology</i> , <b>2008</b> , 8, 449-57	5.1	77
43	Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. <i>Current Opinion in Pharmacology</i> , <b>2008</b> , 8, 393-412	5.1	439
42	Reovirus therapy in cancer: has the orphan virus found a home?. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 1925-35	5.9	15
41	CYP17 inhibition as a hormonal strategy for prostate cancer. <i>Nature Reviews Urology</i> , <b>2008</b> , 5, 610-20		91
40	Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 259-69	12.9	142
39	A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 2075-81	12.9	130
38	Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6302-9	12.9	1685
37	Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. <i>British Journal of Cancer</i> , <b>2008</b> , 98, 1029-33	8.7	124
36	Reovirus activates human dendritic cells to promote innate antitumor immunity. <i>Journal of Immunology</i> , <b>2008</b> , 180, 6018-26	5.3	144
35	Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 6663-73	12.9	106
34	Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 912-23	12.9	86
33	Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4563-71	2.2	713
32	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 911-9	3.5	35
31	Expression profiling of CD133+ and CD133- epithelial cells from human prostate. <i>Prostate</i> , <b>2008</b> , 68, 1007-24	4.2	60
30	A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitin), administered twice daily for 7 days every 21 days. <i>British Journal of Cancer</i> , <b>2007</b> , 96, 29-37	8.7	212
29	Participation of patients with gynecological cancer in phase I clinical trials: two years experience in a major cancer center. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 551-6	4.9	6
28	A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 165-74	3.5	36



27	Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5834-40	12.9	220
26	Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 257-62	2.2	108
25	Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 3611-6	12.9	171
24	A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 532-9	12.9	12
23	Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2675-83	12.9	43
22	Pharmacogenomics of Non-Small Cell Lung Cancer. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , <b>2007</b> , 5, 228-234		
21	Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3753-8	2.2	54
20	D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, S410	8.9	12
19	Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 6187-94	12.9	212
18	703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor. <i>European Journal of Cancer, Supplement</i> , <b>2007</b> , 5, 108	1.6	6
17	Final results of a phase I study of wild-type oncolytic reovirus administered intravenously to patients with advanced cancer. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3572-3572	2.2	2
16	Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 5135-5135	2.2	6
15	Reovirus and other oncolytic viruses for the targeted treatment of cancer. <i>Targeted Oncology</i> , <b>2006</b> , 1, 130-150	5	11
14	A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2841-8	12.9	6
13	573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR. <i>European Journal of Cancer, Supplement</i> , <b>2006</b> , 4, 173-174	1.6	2
12	Update on tubulin-binding agents. <i>Pathologie Et Biologie</i> , <b>2006</b> , 54, 72-84		117
11	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. <i>BJU International</i> , <b>2005</b> , 96, 1241-6	5.6	155
10	Clinical anticancer drug development: targeting the cyclin-dependent kinases. <i>British Journal of Cancer</i> , <b>2005</b> , 92, 7-12	8.7	86

9	ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7555-65	12.9	58
8	Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 211-22	2.2	209
7	Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 203-10	2.2	33
6	Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 96-109	2.2	30
5	Therapeutics targeting signal transduction for patients with colorectal carcinoma. <i>British Medical Bulletin</i> , <b>2002</b> , 64, 227-54	5.4	40
4	Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2647-57	2.2	212
3	Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. <i>British Journal of Cancer</i> , <b>1999</b> , 80, 1786-91	8.7	24
2	Granulocyte macrophage colony-stimulating factor and interleukin-3 regulate chemokine and chemokine receptor expression in bone marrow macrophages. <i>Experimental Hematology</i> , <b>1999</b> , 27, 1735-45	3.1	16
1	Selective Tumour Cell Cytotoxicity by Reoviridae [Preclinical Evidence and Clinical Trial Results] 139-150		